Drug major Ranbaxy Laboratories on Wednesday said it has withdrawn 27 drugs from the US market due to commercial reasons.
124734
Ranbaxy withdraws 27 drugs from US market
575
Mills orders withdrawal of STX agreement
49396
AstraZeneca abandoning anti-ovarian cancer drug
143760
GlaxoSmithKline to cut 130 jobs (gsk)
25251
Placebo forced to cancel entire US tour
17154
No illegal ingredients detected in medicine:
50954
Dealers cleared of selling drugs
86616
Hundreds of herbal medicines to be banned in UK next year
100476
US adds formaldehyde to list of carcinogens
79082
Pharmaceutical industry faces collapse
151455
Merrill Lynch, KASB withdraw investment opinion on 21 stocks
22695
Russia pulls out of us drugs agreement
31497
Drug stocks retreat;
4702
GPC Biotech Reports that Marketing Authorization Application for satraplatin is to be Withdrawn
154580
StatoilHydro to scale down product trading activity
4468
Ranbaxy to shift focus to generics
61600
Ranbaxy has target of Rs 550: